Triple-negative Breast Carcinoma
📧 Sign up to get email alerts when something new happens for Triple-negative Breast Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-06-25Clinical Trial Update: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating pembrolizumab (MK-3475) as adjuvant therapy for triple-negative breast cancer; ongoing ACTIVE_NOT_RECRUITING trial …
-
CLINICAL_TRIALS research · 2025-04-04Clinical Trial Update: Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy [Phase 2]
Phase 2 clinical trial evaluating circulating tumor DNA to guide changes in standard chemotherapy for metastatic HER2-negative breast cancer…
-
CLINICAL_TRIALS trial_result · 2024-02-13Clinical Trial Update: Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative [Phase 2]
Phase 2 trial evaluating liposomal doxorubicin, bevacizumab, and everolimus in locally advanced triple-negative breast cancer predicted inse…
-
CLINICAL_TRIALS trial_result · 2023-09-11Clinical Trial Update: Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer [Phase 1]
Phase 1 trial evaluating chemokine modulation therapy in combination with standard chemotherapy before surgery for early-stage triple-negati…
-
CLINICAL_TRIALS trial_result · 2023-08-03Clinical Trial Update: Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating MAGE-A1-specific T cell receptor-transduced autologous T-cells with atezolizumab for metastatic triple-n…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-08-31Clinical Trial Update: Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies [Phase 1]
Phase 1 trial update of a genetically modified T-cell therapy targeting ROR1 in advanced malignancies, with terminated status and posted res…
-
CLINICAL_TRIALS trial_result · 2020-11-19Clinical Trial Update: Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer [Phase 2]
Phase 2 clinical trial update evaluating mirvetuximab soravtansine as first-line therapy in triple-negative breast cancer; study completed w…
-
CLINICAL_TRIALS trial_result · 2020-05-07Clinical Trial Update: Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer [Phase 1, Phase 2]
Clinical trial update for taselisib plus enzalutamide in androgen receptor positive triple-negative metastatic breast cancer; trial phases 1…
-
CLINICAL_TRIALS trial_result · 2019-01-03Clinical Trial Update: 18F-FSPG PET/CT for Cancer Patients on Therapy [Phase 2]
Phase 2 clinical trial update on 18F-FSPG PET/CT for cancer patients undergoing therapy; study status completed with results posted.